Food News and Research

RSS

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Kaiser Permanente approves over 250 grants and donations totaling $7 million

Kaiser Permanente, one of America's leading health care providers and nonprofit health plans, announced today it approved more than 250 grants and donations nationwide totaling approximately $7 million in the first quarter of 2010. The grants focused on expanding access to nutritious food, providing safe spaces for all ages to increase physical activity, increasing opportunities for continuing education, and eliminating health disparities.

28 Apr 2010

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

FIESTY acronym to improve cognitive function, reduce chances of developing dementia

As researchers learn more about how we age, they're finding that genetics are only half of the story when it comes to developing Alzheimer's disease.

28 Apr 2010

FDA issues warning over faulty components in external defibrillators

About 280,000 external defibrillators used worldwide in health care facilities, public places, or in the home may malfunction during attempts to rescue people in sudden cardiac arrest, the U.S. Food and Drug Administration warned today.

28 Apr 2010

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Smokers who don't quit before radiation therapy for throat, mouth and other head and neck cancers fair significantly worse than those who do, research from the UC Davis Cancer Center has found.

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

AstraZeneca to pay $520 million in largest pharmaceutical civil settlement

AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Life Technologies first-quarter non-GAAP 2010 revenue increases 13% to $887 million

Life Technologies Corporation today announced results for its first quarter ending March 31, 2010. Non-GAAP revenue for the first quarter was $887 million, an increase of 13 percent over the $785 million reported for the first quarter of 2009. Excluding the impact of currency and completed acquisitions and divestitures, organic revenue for the quarter grew 10 percent over the same period in the previous year.

28 Apr 2010

Hana Biosciences announces completion of Marqibo pre-NDA meeting with FDA

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the Company has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to its lead product candidate, Marqibo for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL).

28 Apr 2010

Alair Bronchial Thermoplasty System receives FDA approval to treat asthma in adults

The U.S. Food and Drug Administration today approved the first medical device that uses radiofrequency energy to treat severe and persistent asthma in certain adults.

28 Apr 2010

TYRX receives FDA marketing clearance for AIGISRx ST antibacterial patch for soft tissue repair

TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST, its antibacterial product for the surgical repair of damaged or ruptured soft tissue.

28 Apr 2010

CSI granted FDA unconditional IDE approval for trial of Diamondback 360 System in coronary arteries

Cardiovascular Systems, Inc., has received Food and Drug Administration unconditional Investigational Device Exemption (IDE) approval, allowing the company to proceed with ORBIT II, a pivotal trial to evaluate the safety and effectiveness of CSI's Diamondback 360® System in the coronary arteries. CSI received conditional IDE approval for the ORBIT II study in January 2010.

28 Apr 2010

Priligy - new drug for premature ejaculation

For men suffering from premature ejaculation there may be a new savior in town. The new drug called Priligy is reported to triple the time a man can last in bed. It is currently not licensed in the UK, but is available and licensed for use in a number of other European countries.

28 Apr 2010

Whole grains in diet translate to multiple health benefits: says research

Whole grains in diet can protect an individual from heart diseases say the CSIRO Food Futures National Research Flagship scientists. According to Dr David Topping, the chef research scientist at CSIRO consumption of whole grains in cereal and breads can reduce the risk of several diseases like obesity, diabetes, high blood pressure, some cancers. Legumes and grains could also prevent asthma, gum disease etc.

27 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

27 Apr 2010

Food News and Research

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Kaiser Permanente approves over 250 grants and donations totaling $7 million

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

FIESTY acronym to improve cognitive function, reduce chances of developing dementia

FDA issues warning over faulty components in external defibrillators

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

AstraZeneca to pay $520 million in largest pharmaceutical civil settlement

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Life Technologies first-quarter non-GAAP 2010 revenue increases 13% to $887 million

Hana Biosciences announces completion of Marqibo pre-NDA meeting with FDA

Alair Bronchial Thermoplasty System receives FDA approval to treat asthma in adults

TYRX receives FDA marketing clearance for AIGISRx ST antibacterial patch for soft tissue repair

CSI granted FDA unconditional IDE approval for trial of Diamondback 360 System in coronary arteries

Priligy - new drug for premature ejaculation

Whole grains in diet translate to multiple health benefits: says research

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

The future is bioengineered: Synthetic biology and global sustainability eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News